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Online hemodiafiltration (OL-HDF), the most efficient renal
replacement therapy, enables enhanced removal of small and
large uremic toxins by combining diffusive and convective
solute transport. Randomized controlled trials on prevalent
chronic kidney disease (CKD) patients showed improved
patient survival with high-volume OL-HDF, underlining
the effect of convection volume (CV). This retrospective
international study was conducted in a large cohort of
incident CKD patients to determine the CV threshold and
range associated with survival advantage. Data were
extracted from a cohort of adult CKD patients treated by
post-dilution OL-HDF over a 101-month period. In total, 2293
patients with a minimum of 2 years of follow-up were
analyzed using advanced statistical tools, including cubic
spline analyses for determination of the CV range over which
a survival increase was observed. The relative survival rate
of OL-HDF patients, adjusted for age, gender, comorbidities,
vascular access, albumin, C-reactive protein, and dialysis
dose, was found to increase at about 55 l/week of CV and
to stay increased up to about 75 l/week. Similar analysis of
pre-dialysis β2-microglobin (marker of middle-molecule
uremic toxins) concentrations found a nearly linear decrease
in marker concentration as CV increased from 40 to
75 l/week. Analysis of log C-reactive protein levels showed
a decrease over the same CV range. Thus, a convection dose
target based on convection volume should be considered
and needs to be confirmed by prospective trials as a new
determinant of dialysis adequacy.
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Online hemodiafiltration (OL-HDF) is recognized as the most
efficient renal replacement treatment modality for end-stage
chronic kidney disease (CKD) patients.1 By combining diffu-
sive and convective solute removal principles, uremic blood is
cleansed of both small and large uremic toxins that accumu-
late during CKD.2 The scientific validity, safety, and clinical
benefits of OL-HDF over conventional hemodialysis (HD)
have been supported by several clinical investigations. However,
the findings of recent randomized controlled trials (RCTs)
have renewed interest in improved patient survival attributed
to high-volume OL-HDF and given rise to the concept of a
convection volume-dependent improvement of survival rates
in prevalent end-stage kidney disease (ESKD) patients.3
The hypothesis is supported by four recent studies indicat-
ing that the observed reduction in mortality associated with
OL-HDF correlates with the convection volumes achieved
during therapy. The Dialysis Outcomes and Practice Patterns
Study (DOPPS), an observational study involving 2165 patients,
was the first to identify the role of convection volume in
patient outcome.4 This study showed that 15-25 l of
substitution volume per session (not including weight loss
for extracellular fluid control) resulted in a 35% reduction in
mortality with high-efficiency OL-HDF relative to low-flux
HD (LF-HD).4 Although the CONTRAST Study, an RCT
involving 714 patients, was not able to prove the superiority
of OL-HDF over conventional LF-HD in its primary end
point of mortality, post hoc analysis identified that larger
volumes of convection fluid were associated with a significant
reduction in all-cause and cardiovascular mortality.5 The
Turkish HDF Study, another RCT involving 782 patients,
analyzed survival rates for OL-HDF versus high-flux HD (HF-
HD);6 again, no significant differences in primary end points
were observed, but post hoc analysis indicated significantly
reduced mortality in the subgroup of patients receiving the
largest substitution volumes (417.4 l/session). Finally, the
ESHOL Study, a prospective RCT comparing post-dilution
OL-HDF with HF-HD involving 906 prevalent patients,
reported a 30% reduction in all-cause mortality, 33% in
cardiovascular mortality, and 61% risk reduction in mortality
from stroke. Interestingly, in this study a mean delivered
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convection volume of 23.7 l/session was required to achieve
the reduction in mortality.7 Significantly, this study imple-
mented best clinical practices and coached participating
centers before launching the study to ensure delivery of
target substitution volumes to patients. It is noteworthy that
all four studies involved prevalent dialysis patients with
different dialysis vintages and this may have affected the
outcomes.
In routine clinical practice, a number of approaches can be
undertaken to enhance the convection volume achieved
during each OL-HDF session. The determinants of convec-
tion volume can be categorized in terms of patient-,
prescription-, and technology-related factors.8 However, from
a clinical perspective, the fundamental issue is to ascertain the
optimal total ultrafiltration volume or convection volume
that needs to be delivered to derive the maximal survival
benefit for patients on OL-HDF. Once this target threshold
convection volume has been determined, other patient-
specific strategies that take uremic toxicity and the comorbid
conditions of CKD patients into account could be developed
to improve outcome. Considering this background and the
clinical need to optimize renal replacement therapy prescrip-
tion, we examined a large incident dialysis population with
the objective to ascertain the threshold of convection volume
that needs to be achieved to maximize relative survival.
Convection volume was defined according to the EUDIAL
recommendations as the total ultrafiltration volume obtained
over the entire HDF session, i.e., the sum of the substitution
volume and the intradialytic weight loss achieved to correct
extracellular fluid overload.9 An incident dialysis population
was selected for two reasons, first to reduce exposure time to
chronic uremic complications and dialysis side effects, and
second, to exploit the potential capacity of HDF to reduce
early dialysis mortality.
RESULTS
Demographic, clinical, and biochemical characteristics of the
study population are shown in Table 1. At baseline, mean age
was 67± 15 years and 63% were male. Regarding comorbid-
ities, 30% had diabetes, 16% congestive heart failure, 13%
peripheral vascular disease, and 13% ischemic cerebrovascular
disease.
In total, 2293 patients meeting the predefined criteria
completed the two-year follow-up period and thus comprised
the study cohort. During the 2 years of follow-up, 354 deaths
occurred, 337 patients were censored (29.4% transplanted,
43.6% transferred to another center and 27% lost to follow-up),
and 1602 patients were alive 2 years after the enrolment
period (January 2005 to May 2011, Figure 1).
In this patient cohort, propensity score matching (PSM)
was applied to obtain two matched populations with different
convection volumes (o 54.6 l/week and 4 64.8 l/week).
Table 2 shows patient characteristics of the matched patient
groups after the application of PSM. A total of 408 matched
patients remained with 31 deaths (32 censored) occurring in
the first group (i.e., that with the low convection volume
tertile; convection volumeo 54.6 l/week) and 10 (17 censored)
occurring in the second group (i.e., that with the high
convection volume tertile; convection volume4 64.8 l/week).
Therefore, the second group was associated with a signifi-
cantly higher survival, the survival ratio (95% confidence
interval (CI)) being 3.42 (1.68–6.98) (Po0.001).
The main HDF treatment delivery characteristics are
presented in Table 3. Histograms of the achieved convection
volumes (i.e., the sum of the substitution volumes plus weight
losses during treatment) are presented in Figure 2; the median
convection volume was 21.07 l/session and 62.98 l/week.
The association between weekly convection volume,
considered as a continuous variable, and unadjusted relative
survival rate at 2 years was analyzed and represented as cubic
spline curves in Figure 3. Results are presented both in l/week
and in l/week/m2 body surface area (BSA). As shown, the
relative survival rate starts to increase at around 55 l/week
Table 1 |Baseline patient characteristics
Variable OL-HDF
Age (years; mean, s.d.) 66.7±14.7
Gender (male; %) 63
Height (cm; mean, s.d.) 163.8± 9.5
Pre-dialysis weight (kg; mean, s.d.) 72.6± 15.7
Pre-dialysis systolic blood pressure (mmHg; mean, s.d.) 142.2± 24.4
Pre-dialysis diastolic blood pressure (mmHg; mean, s.d.) 69.8± 13.7
Pre-dialysis heart rate (beats/min) 73.8± 11.2
Renal disease
Diabetes (%) 30
Hypertension (%) 18
Glomerulonephritis (%) 9
Urinary obstruction (%) 1
Polycystic (%) 6
Coronary artery disease (%) 7
Comorbidities
Congestive heart failure (%) 16
Peripheral vascular disease (%) 13
Cerebrovascular disease (%) 13
Chronic pulmonary disease (%) 9
Tumor without metastasis (%) 9
Charlson Comorbidity Index (mean, s.d.) 4.98± 2.07
Vascular access
Fistula (N; %) 2418 (66)
Catheters (N; %) 952 (26)
Grafts (N; %) 293 (8)
Laboratory values
Hemoglobin (g/dl; mean, s.d.) 10.15± 1.29
Albumin (g/dl; mean, s.d.) 3.72± 0.47
Ferritin (ng/ml; median, IQR) 205.05 (256.24)
Creatinine (mg/dl; mean, s.d.) 6.3 ± 2.04
PTH (ng/l; median, IQR) 261.5 (312.25)
Calcium (mg/dl; mean, s.d.) 8.67± 0.62
Sodium (mmol/l; mean, s.d.) 137.8± 3.2
Phosphate (mg/dl; mean, s.d.) 4.55± 1.12
Potassium (mmol/l; mean, s.d.) 4.87± 0.66
CRP (mg/l; median, IQR) 7.19 (18.26)
Abbreviations: CRP, C-reactive protein; IQR, interquartile range; OL-HDF, online
hemodiafiltration; PTH, parathormone.
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(30 l/week/m2) and to plateau at 70–75 l/week (40–45 l/week/m2).
For comparison, the relative survival rates according to the
mean convection volumes achieved in the three main RCTs
were indicated in the graph; the convection volumes reported
in these studies are in alignment with the results of our cubic
spline model analysis.
Patients with more than 90% of treatments in OL-HDF
2634
(TR 198) (SP 628) (PT 1192) (RO 5) 
(IT 289) (RU 47) (CZ 144) (FR 131)
(Enrolment period: 2005–2011)
Patients with more than 60 days
of treatment interruption
2522
OL-HDF
2293
Death
354
Censored patients
(i.e. transplanted, transferred,
other reason)
337 
Patients with less than 10 
recorded dialysis sessions
Patients 
included in
cubic spline
analysis
Patients with CV≥ 54.6 l/week
and ≤64.8 l/week
Propensity score matching
Sample for comparison of
the two matched
populations with different
convection volumes
Patients reached
the study end
1602
CV>64.8 l/week
750
CV>64.8 l/week
204
CV<54.6 l/week
730
CV<54.6 l/week
204
Figure 1 | Flow chart of the study cohort.
Table 2 |Patient characteristics for the matched populations
Variable Lowest convection volume tertiles (o54.6 l/week) Highest convection volume tertiles (464.8 l/week) P-value
Number of patients 204 204
Age (years; mean± s.d.) 63.3± 14.6 64.6± 14.5 0.36
Gender (male; %) 71 67 0.52
Charlson Comorbidity Index 4.5 4.7 0.33
Vascular access
Fistula (%) 78 84 0.15
Catheter (%) 10 8 0.42
Graft (%) 12 8 0.27
CRP (mg/l; median, IQR) 5.9 (14.8) 7.3 (15.6) 0.31
Albumin (g/dl; mean± s.d.) 3.7 ± 0.5 3.7 ± 0.5 0.34
Kt/V (mean± s.d.) 1.5 ± 0.2 1.5 ± 0.2 0.15
Abbreviations: CRP, C-reactive protein; IQR, interquartile range.
1110 Kidney International (2015) 88, 1108–1116
c l in i ca l inves t iga t ion B Canaud et al.: HDF convection volume threshold for improved survival
Weekly convection volume was then analyzed by cubic
spline after adjustment for main confounding factors
(age, gender, Charlson Comorbidity Index, vascular access,
albumin, log C-reactive protein (CRP), and Kt/V) and
presented in Figure 4. Above a weekly substitution volume
of 70.1 L, the relative survival rate increased significantly
(relative survival rate 1.64; 95% CI: 1–2.22). Interestingly, the
adjusted model confirmed that relative survival rate begins
to increase at 56.8 l/week (33 l/week/m2) and flattens off at
~ 75 l/week (45 l/week/m2) with a larger confidence interval.
In addition to this analysis, two biomarkers were investi-
gated, the C-reactive protein (CRP) concentrations as an
indicator of inflammation and the pre-dialysis β2-microglo-
bulin (ß2-M) concentrations as a marker of middle-molecule
uremic toxins. Median pre-dialysis CRP and ß2-M values
were 7.60 mg/l and 19.67 mg/l, respectively (Figures 5 and 6).
Again, a cubic spline analysis was performed to evaluate pre-
dialysis ß2-M concentrations as a function of total weekly
convection volume. As shown in Figure 7, ß2-M concentra-
tions decreased from 24.7 to 22.7 mg/l in an almost
linear manner as weekly convection volume increased up to
75 l/week. On the basis of slope of this relationship, one can
estimate that the ß2-M concentration is reduced by 0.6 mg/l
per each 10 l of additional weekly convection volume. Note
that 91% of patients had no diuresis and no significant
residual kidney function after 6 months on dialysis, i.e., only
anuric patients were considered for this analysis.
A similar cubic spline analysis was performed to evaluate
CRP concentrations as function of convection volume
(l/week) and to further analyze its association with relative
survival rate. As shown in Figure 8, log CRP concentration
decreased in a linear manner with an increase in convection
volume up to ~ 75 l/week. Interestingly, as presented in
Figure 9, relative survival rate improves with a linear decrease
in log CRP levels adjusted for age, gender, Charlson Comorbidity
Index, vascular access, albumin, and Kt/V.
DISCUSSION
The cubic spline modeling approach was applied, for the first
time, to analyze the convection volume delivered during
OL-HDF therapy in association with increased patient
survival. It enables determination of the minimum threshold
convection dose delivered above which a patient survival
benefit is observed. In the overall study population, the
optimal convection dose was between 30 and 45 l/week/m2
BSA (55 to 75 l/week). After adjusting for age, gender, Charlson
Comorbidity Index, vascular access, albumin, CRP, and Kt/V,
the optimal convection dose associated with a significant
improvement of patient outcomes remained almost identical,
being between 32.7 and 45 l/week/m2 BSA (56.8 and 75 l/week).
The relative survival gain is minimal above a convection dose
of over 45 l/week/m2 (75 l/week), meaning that no additional
outcome benefit could be expected at such very high con-
vection volumes. This finding must nevertheless be considered
with a degree of caution, as the number of patients achieving
such very high ultrafiltration volume is quite limited and the
analysis is not powered enough to explore this high con-
vection volume region. In addition, it is important to note
that this convection volume finding approach has only been
evaluated in post-dilution OL-HDF mode, meaning that an
appropriate dilution factor should be applied for all other
substitution modalities (pre-dilution, mixed-dilution, and/or
mid-dilution).9
Convection volume is essentially dependent on blood flow,
type of vascular access, and treatment time.10 These factors
have recently been recognized as being mainly dependent on
Table 3 |HDF treatment delivery characteristics
Parameter Value
Treatment time per session (min; mean± s.d.) 241.5± 14.0
Patients on thrice weekly treatments (%) 96
High-flux dialyzer (%) 100
Dialyzer surface (m2; mean± s.d.) 1.54± 0.20
Effective blood flow (ml/min; mean± s.d.) 404.9± 69.4
Effective dialysate flow (ml/min; mean± s.d.) 506.1± 53.6
Post-dilution HDF (%) 100%
Substitution flow (ml/min; mean± s.d.) 91.4± 13.6
Substitution flow normalized to BSA (ml/min/m2, mean± s.d.) 52.2± 11.4
Weight loss per session (kg; mean± s.d.) 1.54± 0.76
Weight loss as percentage of dry body weight (kg; mean± s.d.) 2.7 ± 0.96
Kt/V (mean± s.d.) 1.53± 0.23
Abbreviations: BSA, body surface area; HDF, hemodiafiltration.
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local clinical practice patterns rather than on patient
characteristics.11 Addressing this potential bias, we matched
the populations with high and low convection volumes
according to the patient characteristics, vascular access,
treatment time, and blood flow. However, we cannot exclude
that different European regions can be differently represented
in terms of convection volume delivered.
A possible question arising from this new method of
analysis is the capacity of the cubic spline model to detect the
level of convection volume adequacy and how it compares
with the standard Kt/V indicator. To elucidate this concern
we proceeded in two ways. First, we conducted the same cubic
spline analysis evaluating relative survival on different levels of
Kt/V (data not shown); the pattern of the relationship with
Kt/V was similar to that observed with convection volume
and identified a minimum Kt/V threshold value of 1.4,
confirming findings from previous cohort studies.12 Second,
we adjusted the cubic spline analysis of relative survival rate
for the main confounding factors (age, gender, Charlson
Comorbidity Index, vascular access, albumin, and log CRP)
and included the Kt/V (Figure 4). These two complementary
analyses confirmed the high predictive value of our findings
and support the concept that targeting an optimal convection
volume is necessary for improving patient outcomes. In any
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case, achieving high convection volumes in HDF is associated
with a 15 to 20% increase of Kt/V, confirming findings of
previous RCT studies.5–7
It is noteworthy that the threshold volume of ~ 55 l/week
determined by our analysis for convection volume adequacy is
consistent with the results of three RCTs5–7 as well as another
recent epidemiological study.13 Even the observational DOPPS
publication actually referred to an almost equivalent substitution
fluid dose (i.e., 15–24.9 l/session).4 Although the small sample
size in the DOPPS study did not permit higher precision, it is
interesting that the minimal threshold of convection dose was
already described in the original paper in 2006.
The importance of the volume of substitution fluid as a
measure of the convection dose was first indicated by Lornoy
et al.,14 who demonstrated its linear relationship with the
ß2-M reduction rate. Then, similar to Kt/V for small molecules,
a denominator was sought to adjust the dose for body size or
body surface area as a surrogate for patient metabolic
characteristics. Several anthropometric parameters have been
proposed,9 but Maduell et al.7 was unable to find a better fit
than the simple substitution fluid volume or total convection
volume. In our analysis, the adjusted BSA normalized results
were very similar to the unadjusted BSA normalized results,
but that could be due to the relative anthropometric homo-
geneity of the European population. Extrapolation to different
ethnicities needs to be tested. In agreement with the asso-
ciation between ß2-M levels and survival as found by Cheung
et al.,15 Figure 6 shows that pre-dialysis ß2-M concentrations
would be easily maintained below 27.5 mg/l in patients on
HDF, this being the threshold value for increased mortality
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risk in the HEMO study. In 1996, Locatelli et al.16 showed a
difference in ß2-M in the range of 10 mg/l between LF-HD
and HF-HD. Further differences between HF-HD and
HDF were not found, but in those years the treatment
was still delivered with bags and the substitution volume was
significantly lower than today. According to our results
(Figure 7), a further decrease in pre-dialysis ß2-M levels may
be achieved by increasing the convection volume up to 45 l/
week/m2 (75 l/week). On the basis of the convection-volume
dependency relationship reported here, ß2-M concentrations
would be reduced by 0.6 mg/l for every 10 l of additional
convection volume per week. It is also shown that achieving
mid-week pre-dialysis ß2-M concentrations lower than
25 mg/l is routinely feasible with high-volume OL-HDF.14,17
It is thus tempting to speculate that maintaining ß2-M
concentrations below 27.5 mg/l over a period of time may
have contributed to the protective effects of OL-HDF, as
suggested by the post hoc analysis of the HEMO Study.15 A
recent study18 in non-dialysis CKD patient cohorts clearly
identified that higher circulating ß2-M concentrations are
associated with an increased risk of all-cause mortality,
and also with an increased occurrence of severe or fatal
cardiovascular events. In that study it is impressive that the
threshold value of ß2-M concentration that was associated
with a lower mortality risk was as low as 8.4 mg/l, meaning
that reducing ß2-M concentration targets to as low as possible
is likely to provide additional cardiovascular protective effects
in dialysis patients. A recent randomized cross-over study19
exploring uremic toxin removal in conventional (4 h) and
extended (8 h) HF-HD and HDF showed that pre-dialysis
ß2-M levels concentrations could be stabilized around 20 mg/l
by achieving a 85.5% reduction in ß2-M levels per HDF
session.20
In addition, it is also interesting to note that the potential
confounding role of residual kidney function could be ruled
out in our study, as 490% of the incident patients studied
had lost significant diuresis after 6 months. This clinical
observation appears to be the likely consequence of a strict
policy of extracellular fluid volume control implemented in
our network following the findings of the Tassin study.21
A novel and interesting finding of our study is the inverse
association relationship identified between convection volume
and the inflammation status of the patients. As presented
in Figure 8, log CRP decreases with increasing convection
volume, at least up to ~ 45 l/week/m2 (75 l/week), even after
adjustment for main confounding factors. It is of importance
to note that this beneficial effect may also be related to the
convection volume. In addition, the cubic spline analysis
revealed that the relative survival rate is inversely associated
with log CRP levels, with a threshold value of 10 mg/l
(Figure 9).
As cubic spline analysis is based on a multiple polynomial
structure, it allows the modeling of complex relative survival
rate functions (as opposed to the classical Cox regression).
This was fundamental to deriving an accurate approximation
of the association between survival rate and convection
volume and the relationship between convection volume and
pre-dialysis ß2-M and CRP levels. To further enhance the
independent and predictive value of convection volume on
relative survival rate of incident dialysis patients, the cubic
spline model analysis was adjusted for main confounding
factors (age, gender, Charlson Comorbidity Index, vascular
access, albumin, CRP, and Kt/V). A limitation of the per-
formed analysis is that the convection volume for each patient
is represented by the mean of all convection volumes
delivered for the study period. However, the s.d. and the
coefficient of variation of the convection volumes were 7.38 l/
week and 0.11, respectively, indicating a quite homogeneous
individual prescription and that the averaged values are
quite representative of the delivered convection treatment.
A further limitation is that the relatively limited number of
patients does not allow a more precise estimation of the
relative survival at high convection volumes.
In conclusion, convection dose is a strong determinant
factor of survival of patients on OL-HDF. The original finding
of this study is that improvement of relative survival rate
has a convection volume dependency that is almost linear
from 30 l/week/m2 (~ 55 l/week) to 45 l/week/m2 (75 l/week).
Furthermore, we can speculate that early start of OL-HDF can
be beneficial for reducing mortality of HD patients. Clinical
practice should be tailored to target and achieve an optimal
convection volume. The improvement in survival is linearly
associated with a decrease of log CRP and ß2-M levels,
suggesting that the observed benefit may be attributed
predominantly to reducing inflammation and middle mole-
cule elimination. We cannot exclude the possibility that a
higher frequency and/or duration of treatment may have
further impact on the convection volume results of our study,
as our analysis was based mainly on a thrice weekly 4-hour
treatment schedule. A convection dose target based either on
convection volume or on pre-dialysis ß2-M concentrations
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Figure 9 |Cubic spline analysis of relative survival rate (with 95%
confidence interval) versus log C-reactive protein values adjusted
for age, gender, Charlson Comorbidity Index, vascular access,
albumin, and Kt/V.
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should now be considered and confirmed as a new deter-
minant of dialysis adequacy.
MATERIALS AND METHODS
In this retrospective observational study, data were extracted from a
cohort of 2634 adult patients on in-center OL-HDF treatment in a
large private dialysis network between January 1, 2005 and May 31,
2013. The participating countries were Czech Republic, France, Italy,
Portugal, Romania, Russia, Spain, and Turkey. To select a dialysis
population of incident patients (i.e., patients admitted to a participating
clinic within 90 days of dialysis initiation) receiving uninterrupted OL-
HDF treatment over the time of observation, different selection criteria
were applied (see Figure 1). To assure exclusivity of HDF treatment,
patients were excluded from the analysis when the percentage of HDF
sessions over the entire period of treatment observation waso90%. To
ensure that HDF treatment was delivered also in a continuous manner,
patients with 460 days of treatment interruption (e.g., due to
hospitalization, holidays) were excluded. Finally patients having
o10 OL-HDF treatments during the observation period were also
excluded because of insufficient data for analysis.
After application of the selection criteria, 2293 patients remained
in the study. This group constituted the basis for the subsequent
determination of the threshold of convection volume above which
survival was increased.
HDF treatment prescription is sensitive to the total substitution
volume delivered per session. This is a function of the instantaneous
substitution flow and the duration of the session. Since January 2012,
a substitution volume of 21 l/session has been specified as the target
substitution volume throughout the clinic network; effective
achievement is continuously monitored by the quality control
system. The weight loss achieved by ultrafiltration corresponds to the
interdialytic weight gain adjusted to the dry weight target. The total
ultrafiltered volume or effective convection volume removed during
the session is the sum of these two components, substitution
volume and ultrafiltration weight loss. Main factors affecting
HDF performance (e.g., blood flow, dialysate flow, treatment time,
anticoagulation, manual or automatic ultrafiltration control by the
HDF machine)10 are subject to regional or local practice patterns.
Implementation of best practice guidelines within the network is
supported by educational materials and local expertise.
All data were obtained using electronic medical records from the
European Clinical Database (EuCliD) and were collected according to
company standard clinical protocols and procedures.22 All patients
consented that their data can be used in an anonymized form for
scientific research. Collected variables included demographics,
medical history, underlying renal disease, comorbidities, vascular
access, treatment prescriptions, laboratory data, detailed records of
each delivered dialysis treatment and events (hospitalizations, death
and their causes). All blood samples for laboratory evaluations were
taken at the mid-week session with the following frequencies: Kt/V
monthly, CRP quarterly, and ß2-M every 6 months.
BSA was estimated according to the formula of Mosteller:
BSA= ([Height (cm) ×Weight (kg)]/ 3600)(1/2). The not normally
distributed variable CRP was log-transformed and considered as time
averaged log CRP over the observation period. ß2-M was considered
as single measurements.
Statistical analyses
To assess the association between convection volume and survival,
PSM was applied. For the computation of PSM the variables that
might influence convection volume and survival were considered.
These included age, gender, Charlson Comorbidity Index, vascular
access, albumin, CRP, and Kt/V. All these variables, except gender
and vascular access, were allocated to four categories considering the
quartiles of the distribution as thresholds.
All 2293 patients were considered for the selection of two
matched populations based on PSM.23 Specifically, the lowest and
highest achieved convection tertiles of average convection volume
were used to define the two populations (54.6 l/week and 64.8 l/
week, respectively) Using PSM, an adjusted population of 408
patients (41 deaths) was considered for survival rate computation
based on a Cox regression model.24
All 2293 patients were also analyzed by cubic spline methodology
to better understand the continuous relationship between convection
volume and survival and to establish the threshold of the convection
volume offering a significant survival benefit.
To define the threshold where convection volume begins to become
beneficial, and to identify the limit at which no additional benefit can be
detected, unadjusted and adjusted associations between convection
volume and survival were estimated using multivariable Cox propor-
tional hazards models combined with cubic spline analysis as described
by Flythe et al.25 This approach is complementary to PSM: first, it
provides a clue to understanding the continuous relationship between
convection dose and survival; second, it strengthens the analysis since
the whole patient cohort is used, and it accounts also for confounding
effects through the adjustment for covariable predictors of mortality.26
The cubic spline model was also chosen as it is a flexible method
that does not require a priori assumptions about the shape of the
distribution characterizing the data set.27 The smoothness (data
fitting) of the model can be easily controlled by means of the number
of polynomials (number of knots) of the spline.
The first set of data used to perform the cubic spline analysis for
convection volume was the entire population that had 2 years of
follow-up. The first two cubic spline analyses (Figure 3) were non-
adjusted and had four knots each, placed at 20, 40, 60, and 80
percentiles for convection volume (36.4, 54.2, 61.8, and 67.7 l/week,
respectively) and of convection volume normalized to BSA (20.1,
29.6, 34.1, and 38.3 l/week/m2, respectively).
The second two cubic spline analyses (Figure 4) were adjusted for
age, gender, Charlson Comorbidity Index, vascular access, albumin,
log CRP, and Kt/V, and were designed in a similar manner as the
non-adjusted curves. The 20, 40, 60, and 80 percentiles for
convection volume were 47.9, 57, 62.6, and 67.8 l/week, respectively,
and for the convection volume normalized for BSA they were 26.0,
30.9, 34.7, and 38.5 l/week/ m2, respectively.
Cubic spline analysis was also used to model the association of
convection volume with pre-dialysis ß2-M (Figure 7) and log CRP
(Figure 8) levels, whereby only the latter was adjusted for age,
gender, Charlson Comorbidity Index, vascular access, albumin, and
Kt/V. Both the splines have a single knot at the median of convection
volume, 67.9 l/week for ß2-M and 60.2 l/week for CRP.
Convection volume was calculated either as total weekly
convection volume or as weekly and normalized by BSA, always
applying a three treatments per week factor.
A P-value ofo 0.05 was considered as significant. All descriptive
statistics were performed by Matlab 2013b software; cubic spline
analysis was done using R 3.0.1.
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